If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.



Bristol-Myers Squibb Fined In Plavix Dispute

by Glenn Hess
April 6, 2009 | A version of this story appeared in Volume 87, Issue 14

Bristol-Myers Squibb will pay a $2.1 million civil penalty—the largest allowed by law—for failing to inform the Federal Trade Commission (FTC) about its efforts to delay generic competition for its blockbuster blood-thinning drug Plavix. FTC says the fine stems from charges that BMS entered into agreements with Canadian drugmaker Apotex to delay the launch of a generic form of Plavix in the U.S. for several years, in exchange for payments from BMS. The complaint alleges that BMS “also orally stated, among other things, that it would not compete with Apotex during the first 180 days after Apotex did market its new generic drug.” FTC says the arrangement violated the reporting requirements of the Medicare Modernization Act of 2003, which mandates that unwritten understandings be described in writing and provided to the commission along with written agreements. “Firms submitting required filings with FTC have an absolute obligation to be forthright and complete,” says David P. Wales, acting director of FTC’s Bureau of Competition. “Filing firms must understand that they can’t reach oral understandings and simply omit them from their required filings.” In May 2007, BMS paid $1 million to settle criminal charges that it lied to the Department of Justice about its Plavix agreement with Apotex.


This article has been sent to the following recipient:

Chemistry matters. Join us to get the news you need.